Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects
IEEE/ACM Transactions on Computational Biology and Bioinformatics · 2023
DOI: 10.1109/tcbb.2022.3141697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2023. Verfasst von Rizwan Qureshi und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 169 Literaturangaben. Gefördert von: Hong Kong Research Grants Council, Hong Kong Innovation and Technology Commission, City University of Hong Kong.
Abstract (Originalsprache)
Lung cancer is a major cause of cancer deaths worldwide, and has a very low survival rate. Non-small cell lung cancer (NSCLC) is the largest subset of lung cancers, which accounts for about 85% of all cases. It has been well established that a mutation in the epidermal growth factor receptor (EGFR) can lead to lung cancer. EGFR Tyrosine Kinase Inhibitors (TKIs) are developed to target the kinase domain of EGFR. These TKIs produce promising results at the initial stage of therapy, but the efficacy becomes limited due to the development of drug resistance. In this paper, we provide a comprehensive overview of computational methods, for understanding drug resistance mechanisms. The important EGFR mutants and the different generations of EGFR-TKIs, with the survival and response rates are discussed. Next, we evaluate the role of important EGFR parameters in drug resistance mechanism, including structural dynamics, hydrogen bonds, stability, dimerization, binding free energies, and signaling pathways. Personalized drug resistance prediction models, drug response curve, drug synergy, and other data-driven methods are also discussed. Recent advancements in deep learning; such as AlphaFold2, deep generative models, big data analytics, and the applications of statistics and permutation are also highlighted. We explore limitations in the current methodologies, and discuss strategies to overcome them. We believe this review will serve as a reference for researchers; to apply computational techniques for precision medicine, analyzing structures of protein-drug complexes, drug discovery, and understanding the drug response and resistance mechanisms in lung cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Förderung
- Hong Kong Research Grants Council
- Hong Kong Innovation and Technology Commission
- City University of Hong Kong
Zitieren
APA
Qureshi, R., Zou, B., Alam, T., Wu, J., Lee, V. H. F., & Yan, H. (2023). Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects. IEEE/ACM Transactions on Computational Biology and Bioinformatics. https://doi.org/10.1109/tcbb.2022.3141697
Vancouver
Qureshi R, Zou B, Alam T, Wu J, Lee VHF, Yan H. Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects. IEEE/ACM Transactions on Computational Biology and Bioinformatics. 2023. doi:10.1109/tcbb.2022.3141697
BibTeX
@article{Qureshi2023,
author = {Qureshi, Rizwan and Zou, Bin and Alam, Tanvir and Wu, Jia and Lee, Victor H F and Yan, Hong},
title = {Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects},
journal = {IEEE/ACM Transactions on Computational Biology and Bioinformatics},
year = {2023},
doi = {10.1109/tcbb.2022.3141697}
}
EUVIMED